Mounjaro vs Jardiance
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| US Mounjaro | US Jardiance | |
|---|---|---|
| Generic name | tirzepatide | empagliflozin |
| Drug class | GIP/GLP-1 Receptor Agonist | SGLT2 Inhibitor |
| Treats | Type 2 diabetes | Type 2 diabetes, heart failure, chronic kidney disease |
| Category | Diabetes | Diabetes |
| Manufacturer | Eli Lilly | Boehringer Ingelheim/Eli Lilly |
| Year approved | 2022 | 2014 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $350M | $280M |
| Common side effects | Nausea, Diarrhea, Decreased appetite, Vomiting | Urinary tract infections, Yeast infections, Increased urination, Low blood pressure |
Jardiance
Frequently asked questions
Is Mounjaro or Jardiance better?
Neither is universally "better." Mounjaro (tirzepatide) and Jardiance (empagliflozin) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Mounjaro and Jardiance?
Mounjaro is a GIP/GLP-1 Receptor Agonist made by Eli Lilly, while Jardiance is a SGLT2 Inhibitor made by Boehringer Ingelheim/Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Mounjaro has the larger estimated TV advertising budget of the two.